CAR T Cell Therapy–Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity?

Highlights •CD19-specific CAR T cell therapies represent a new breakthrough in the treatment of relapsing and refractory hematological malignancies. •The adverse effects observed in early trials and recent retrospective studies have suggested that CAR T cell therapies are associated with cardiovascular toxicity. •Prospective studies using multimodality cardiac imaging and novel and established biomarkers are needed to define the cardiac safety of CAR T cell therapies to fully harness their life-saving potential.